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ardiovascular disease (CVD) is the leading cause of death 
in Australia.1 New treatment guidelines based on absolute  
CVD risk estimates were adopted in 2012.2 General practi- 
tioners are central to implementing these guidelines, as about 
90% of people in Australia consult GPs each year,3 but large ev- 
idence–practice gaps in the management of people with CVD in 
general practice have been reported.4 
We therefore examined implementation of the 2012 CVD guide- 
lines in general practice by analysing baseline electronic medical 
record (eMR) data from two clinical trials of computer-supported 
interventions for improving CVD care conducted during 2015– 
2018, the INTEGRATE5 and Q Pulse studies.6 Our analysis is 
based on data for 102 225 patients from 95 general practices in 
four Australian states and territories. The study was approved 
by the Human Research Ethics Committees of the University of 
Sydney (reference, 2015/616) and the University of Notre Dame 
(reference, 014105S/016011S). 
De-identified eMR data — demographic information, medical 
history, prescribed medications, smoking status, blood pres- 
sure, low-density lipoprotein cholesterol (LDL-C) levels — were 
extracted at each practice with the CAT 4 Clinical Audit tool 
(PenCS). Absolute CVD risk was calculated according to cur- 
rent guidelines2 and patients with a documented CVD diagno- 
sis (coronary heart disease, cerebrovascular disease, peripheral 
vascular disease, left ventricular hypertrophy, atrial fibrillation, 
or heart failure) were identified (Box 1). 
Guideline-recommended treatment was defined as the pre- 
scribing of blood pressure- and lipid-lowering medications for 
patients at high CVD risk, and also of antiplatelet or anticoagu- 
lant medications for patients with established CVD (Supporting 
Information). The proportions of patients who had attained 
treatment targets for blood pressure (< 140/90 mmHg for pa- 
tients at high CVD risk, < 130/80 mmHg for people with estab- 
lished CVD or diabetes) and LDL-C level (< 2.0 mmol/L) were 
calculated. 
Of 102 225 patients in the two studies, 10 631 (10.4%) had estab- 
lished CVD and 12 983 (12.7%) clinically high risk conditions; 
estimated CVD risk was high for 2760 (2.7%) and low or inter- 
mediate for 46 205 people (45.2%), while the available eMR data 
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diastolic blood pressure above 110 mmHg, or total cholesterol level exceeding 7.5 mmol/L. ◆ 
conditions: people with diabetes and over 60 years of age, diabetes and albuminuria, estimated glomerular filtration rate below 45 mL/min/1.73 m2, systolic blood pressure above 180 mmHg, 
* Including Aboriginal and Torres Strait Islander people aged 35 years or more and non-Indigenous Australians aged 45 years or more, and people of any age at clinically high risk of CVD. 
Regular attendance was defined as attending the practice at least three times during the preceding 24 months and at least once during the preceding six months. † Australian Cardiovascular 
Risk Calculator (based on the Framingham Risk Equation). High CVD risk defined as either 5-year risk exceeding 15%, or presence of a clinically high-risk condition.2 ‡ Clinically high-risk 
1 Flow chart of patient risk and treatment identification 
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Among patients with established CVD, 6038 (56.8%) had been 
prescribed the guideline-recommended treatments; blood pres- 
sure targets had been achieved by 4114 patients (38.7%) and LDL 
targets by 5645 (53.1%). Among the 15 743 patients at high CVD 
risk, 6486 (41.2%) were prescribed recommended treatments; 
8988 (57.1%) had achieved blood pressure targets and 5714 (36.3%) 
LDL-C targets (Box 1, Box 2). 
Our findings indicate that primary care management of patients 
with CVD is sub-optimal. Adopting the absolute risk assessment 
approach has not improved adherence to management guide- 
lines,4,7 similar to the experience in Europe, Canada, and the 
United Kingdom.8,9 
We may have underestimated CVD risk for patients already re- 
ceiving blood pressure- and lipid-lowering therapies. Risk esti- 
mates were based on information in eMR structured data fields; 
additional information recorded as free text was not considered. 
Rural and Aboriginal Medical Service practices were under- 
represented in our practice sample. 
GPs play essential roles in identifying patients at  risk  of  CVD 
and managing their treatment,10 but ensuring their adherence to 
evidence-based recommendations is challenging. While risk assess- 
ment tools are important, overcoming patient, GP, and health sys- 
tem barriers to changes in care delivery will be critical to progress. 
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ommended (Supporting Information). † High cardiovascular disease risk: < 140/90 mmHg; 
established cardiovascular disease or diabetes: < 130/80 mmHg. ‡ < 2 mmol/L. ◆ 
* One or more blood pressure-lowering medications and a statin; for people with estab- 
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